CD79A and COVID-19: Besides, among the IgA-negative COVID-19 subjects, six patients had constitutive immune deficiencies that might have hampered the development of an anti-SARS-CoV-2 IgA response, including leukemia, lymphomas, very advanced age, and chemotherapy treatment due to concomitant cancer.